Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facility and delays in the approval process for its flagship product. Hagens Berman urges investors in Humacyte who suffere ...